Home ›
Kidney Cancer Trials ›
NCT07426484
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC).
The name of the drug involved in this research study is:
-cosibelimab (a type of an anti-PD-L1 antibody)
Trial Details
NCT ID NCT07426484
Phase PHASE4
Sponsor Dana-Farber Cancer Institute
Status RECRUITING
Cancer Type Kidney Cancer
Interventions Cosibelimab Prednisone Sirolimus Everolimus
Locations (sample) Boston, Massachusetts, United States|42.35843,-71.05977 Boston, Massachusetts, United States|42.35843,-71.05977
Key Eligibility Criteria
COHORT A: Participant must have a history of kidney transplant (at least 6 months prior to enrollment). (A history of more than one kidney transpla… COHORT B: Participant must have a diagnosis of a hematologic malignancy, including chronic myeloproliferative neoplasm (CMN) or an indolent non-Hod… Examples of indolent non-Hodgkin's lymphomas (NHL), including but not limited to: Chronic lymphocytic leukemia (CLL)
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Kidney Cancer Trials on Trialify →